January 24, 2025
1 min read

Moderna Secures Contract to Supply mRNA COVID-19 Vaccine in the European Union

moderna vaccine in close up photography
Photo by Mufid Majnun on Pexels.com

New agreement enables participating nations to diversify their mRNA vaccine supply and access pre-filled syringe formats for enhanced efficiency.

Moderna, Inc. (NASDAQ: MRNA) has been selected to supply its mRNA COVID-19 vaccine to the European Union (EU), Norway, and North Macedonia. This agreement, spanning up to four years, allows 17 participating countries to secure Moderna’s vaccine, including innovative formats such as pre-filled syringes.

Chantal Friebertshäuser, Senior Vice President and General Manager for Europe & Middle-East at Moderna, emphasized the significance of the agreement: “This partnership enables Moderna to bolster national COVID-19 vaccination efforts across Europe. Diversifying vaccine supply and offering formats like pre-filled syringes are critical to improving vaccination rates, streamlining campaigns, and strengthening public health security.

The inclusion of pre-filled syringes is a key feature of the agreement. This format is favored by healthcare professionals as it reduces the risk of administration errors and saves valuable time, ultimately enhancing the efficiency of vaccination programs.

In September 2024, the European Commission (EC) approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, which targets the JN.1 variant of SARS-CoV-2. This authorization allows the vaccine to be used for active immunization in individuals aged six months and older, providing protection against COVID-19 caused by the virus.

For more information, visit Moderna’s official website.

Key Highlights of the Agreement:

  1. Diverse Vaccine Supply: Participating countries gain access to Moderna’s mRNA COVID-19 vaccine for up to four years.
  2. Pre-filled Syringes: This format minimizes administration errors and improves vaccination campaign efficiency.
  3. Updated Vaccine Formulation: The EC-approved Spikevax targets the JN.1 variant, ensuring broader protection.

This agreement underscores Moderna’s commitment to supporting global health initiatives and adapting to the evolving needs of vaccination programs.

Sources:

Avelino Dominguez

Biologist - Teacher - Statistician #SEO #SocialNetwork #Web #Data ♟Chess - Galician

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

scientists in laboratory
Previous Story

Moderna suministrará su Vacuna de ARNm Contra el COVID-19 en la Unión Europea

ipv4
Next Story

IPv4 Addresses y IPv4 Subnetting: Guía Básica

Top

Don't Miss

scientists in laboratory

Moderna suministrará su Vacuna de ARNm Contra el COVID-19 en la Unión Europea

El acuerdo permite a los países…
us stock market holidays 2025

US Stock Market Holidays 2025

The U.S. Stock Exchange, which includes…